Headshot photo of Aysegul Ors, Ph.D.

Aysegul Ors, Ph.D.

  • Associate Scientist, CEDAR, OHSU Knight Cancer Institute, School of Medicine


Aysegul Ors, Ph.D. uses single-cell transcriptomic and multi-omic assays to study the role of transcriptional, genetic and epigenetic heterogeneity in tumors. She’s interested in uncovering the role of heterogeneity in tissue transformation and tumor progression in hormone responsive cancers such as breast cancer. Previously, she studied the role of histone variants in the epigenetic regulation of transcription and mitosis. Aysegul conducted her graduate research in the Institute of Advanced Biosciences at the University of Grenoble, France and received her Ph.D. in molecular biology and genetics from Bilkent University in Ankara, Turkey.

Education and training

    • M.A.Sc., 2009, University of Technology of Compiegne
    • B.S.E., 2009, University of Technology of Compiegne
    • M.Eng., 2009, University of Technology of Compiegne
    • Ph.D., 2017, Bilkent University

Areas of interest

  • Single-cell multi-omics (scNMTseq)
  • Single-cell RNA-seq
  • Epigenetic regulation
  • Histone variants
  • DNA methylation
  • Tumor heterogeneity
  • Breast Cancer


Selected publications

  • Ors A, Papin C, Favier B, Roulland Y, Dalkara D, Ozturk M, Hamiche A, Dimitrov S, Padmanabhan K. Histone H3.3 regulates mitotic progression in mouse embryonic fibroblasts. Biochemistry and Cell Biology, 2017. doi: 10.1139/bcb-2016-0190.
  • Ors A., Chitsazan A.D., Doe A.R., Mulqueen R.M., Ak C., Wen Y., Haverlack M., Handu M., Naldiga S., Saldivar J.C.  and Mohammed H. Estrogen regulates divergent transcriptional and epigenetic cell states in breast cancer. Nucleic Acids Res. 2022. https://doi.org/10.1093/nar/gkac908
  • Nardone A., Qiu X., Spisak S., Nagy Z., Feiglin A., Feit A., Cohen Feit G., Xie Y., Font-Tello A., Guarducci C., Hermida-Prado F., Syamala S., Lim K., Munoz Gomez M., Pun M., Cornwell M., Liu W., Ors A., Mohammed H., Cejas P., Schiff R., Long H.W., Metzger Filho O., Jeselsohn R. A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer. Cancer Res. 2022. https://doi.org/10.1158/0008-5472.CAN-21-3186
  • Le H.H., Cinaroglu S.S., Manalo E.C., Ors A., Gomes M.M., Sahbaz B.D., Bonic K., Marmolejo Origel C.A., Quentel A., Plaut J.S., Kawashima T.E., Ozdemir E.S., Malhotra S.V., Ahiska Y., Sezerman U., Akcapinar Bayram G., Saldivar J.C., Timucin E. and Fischer J.M. Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells. EBioMedicine, 2021.https://doi.org/10.1016/j.ebiom.2021.103646
  • Ors A., Papin C., Favier B., Roulland Y., Dalkara D., Ozturk M., Hamiche A., Dimitrov S., Padmanabhan K. Histone H3.3 regulates mitotic progression in mouse embryonic fibroblasts. Biochemistry and Cell Biology, 2017. https://doi.org/10.1139/bcb-2016-0190
  • Ozen C., Yildiz G., Dagcan A.T., Cevik D., Ors A., Keles U., Topel H., Ozturk M. Genetics and epigenetics of liver cancer. New Biotechnology, 2013 May 25;30(4):381-4. Review article. https://doi.org/10.1016/j.nbt.2013.01.007